{
    "nctId": "NCT00897091",
    "briefTitle": "S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil",
    "officialTitle": "Molecular Predictors of Outcome on CAF Plus Tamoxifen Versus Tamoxifen Alone in Postmenopausal Women With Node Positive, Receptor Positive Breast Cancer [NCI Correlative Science Reference No. # 8814A-ICSC]",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 750,
    "primaryOutcomeMeasure": "Disease-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Node-positive disease (pT1-3a, pN1-2 \\[clinical N0-1\\], M0)\n* Previously enrolled in SWOG-8814, a treatment clinical trial, and in SWOG-9445, a companion tissue banking study\n* Tumor block or unstained sections available from initial diagnosis in the SWOG archive\n\n  * Sufficient tumor in block or unstained sections\n  * Patients for whom only unstained slides are available must have acceptable reverse-transcriptase-polymerase chain reaction (RT-PCR) profiles\n* Sufficient RNA (\u2265 300 ng) for RT-PCR analysis with the Oncotype DX 21 gene assay\n* Average normalized cycle threshold for the 5 reference genes \u2264 35\n* Follow-up data from the SWOG-8814 clinical trial obtained from the patient\n* Hormone receptor status:\n\n  * Estrogen and/or progesterone receptor positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}